KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.

Christoph U Correll, Suresh Durgam, Susan G Kozauer, Hassan D Lakkis, Changzheng Chen, Kimberly E Vanover, Sharon Mates, Robert E Davis

Int Clin Psychopharmacol 41(2) 120-129

PMID40694062
PMCIDPMC12854375
DOI10.1097/YIC.0000000000000597
发表日期2025-07-22
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图。
摘要

摘要

This Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of lumateperone to treat bipolar depression. Patients (18-75 years) with bipolar I or bipolar II disorder experiencing a major depressive episode were randomized 1:1:1 to 6-week lumateperone 28 mg ( n = 183), lumateperone 42 mg ( n = 185), or placebo ( n = 186). Primary and key secondary endpoints were change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total score and time to first sustained response (≥50% reduction from baseline in MADRS Total score), respectively. Safety assessments included adverse events, extrapyramidal symptoms (EPS), laboratory evaluations, and vital signs. Neither dose of lumateperone achieved significant improvement vs. placebo ( P > 0.05) in the primary endpoint (MADRS Total score, least squares mean difference vs. placebo: 28 mg, 0.9; 42 mg, -1.0) or in the key secondary endpoint (MADRS Total time to first sustained response hazard ratio vs. placebo: 28 mg, 1.00; 42 mg, 0.93), likely due to a high placebo response. Both lumateperone doses were well tolerated, with low EPS risk and minimal changes in weight, prolactin, and cardiometabolic or endocrine parameters. While study efficacy objectives were not met, both doses of lumateperone were generally safe and well tolerated in patients with bipolar depression.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition (CONSORT diagram). ITT, intent to treat.
非 KM Figure
Fig. 2Fig. 2 LS mean change from baseline in MADRS total score by visit in the ITT population (a), bipolar I disorder subgroup (b), and bipolar II disorder subgroup (c). * P < 0.05 ** P < 0.01 MMRM (not adjusted for multiplicity). ITT, intent-to-treat; LS, least squares; MADRS, Montgomery-Åsberg Depression Rating Scale; MMRM, mixed-effects model for repeated measures.
非 KM Figure